Skip to main content
. Author manuscript; available in PMC: 2012 Nov 1.
Published in final edited form as: J Neurochem. 2011 Sep 21;119(3):617–629. doi: 10.1111/j.1471-4159.2011.07424.x

Figure 2.

Figure 2

(a) Densitometry from immunoblotting was utilized to confirm quantitative values measured using mass spectrometry. Proteins were measured that were significantly affected by both lithium and valproate treatments and had commercially available antibodies. (b) Similar to spectrometry results, Western blotting showed significant increases in Grm3 expression in both treatment groups. (c) Levels of ankyrin 3 (ankyrin G) were significantly increased in the lithium treatment group, while they exhibited a trend in the valproate treatment (p=0.06, *p<0.05, ***p< 0.001.